Evidence map›Paper›PMID 31802415›Full record

Observational studyJournal of thrombosis and thrombolysis2020

Pharmacist involvement in clinical assessment and laboratory testing for heparin-induced thrombocytopenia.

Amanda J Condon, Adam J Hood, Katie L Willenborg, Kraig Kumfer, Anne E Rose

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amanda J CondonDepartment of Pharmacy, University of New Mexico Hospitals, Albuquerque, NM, 87106, USA.
Adam J HoodDepartment of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Katie L WillenborgDepartment of Pharmacy, William S. Middleton Memorial Veterans Hospital, Madison, WI, 53792, USA.
Kraig KumferDepartment of Medicine, UW Health, Madison, WI, 53792, USA.
Anne E RoseDepartment of Pharmacy, University of Wisconsin (UW) Health, 600 Highland Avenue, Madison, WI, 53792, USA. arose@uwhealth.org.ORCID http://orcid.org/0000-0002-4658-9733

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparin-induced thrombocytopenia (HIT) is a rare adverse drug reaction. The anti-PF4 antibody assay (ELISA) is utilized to assist in the clinical evaluation of HIT due to its high negative predictability and wide-spread availability. However, it also associated with false positive results. The 4T score can assist in predicting an individual's risk for HIT and the need for further laboratory testing. This was a single-center prospective observational cohort study. Orders for HIT testing were sent via page to a clinical pharmacist to calculate a 4T score. If low risk, the pharmacist contacted the ordering prescriber to recommend discontinuation of laboratory testing. During the study, a clinical support tool was implemented to assist prescribers with ordering HIT tests. The study was divided into a pharmacist intervention group and a control group. A total of 303 pages were received. One hundred nine were missed due to unavailability of the pharmacist at time of page. A pharmacist reviewed 194 pages and intervened on 132. One hundred seven were scored as low risk, 70 as intermediate risk and 9 as high risk. Pharmacist intervention resulted in discontinuing 64 ELISA and 11 serotonin release assay tests. The clinical support tool resulted in a yearly decrease of HIT testing by 27%. Laboratory cost savings totaled $11,000 but did not include avoidance of laboratory technician or drug cost. Pharmacist involvement in the clinical assessment of HIT and the use of a support tool resulted in the reduction of HIT tests in low risk patients.

Indexed as

PharmacistsProcedures and Techniques UtilizationThrombocytopeniaAntibodiesAnticoagulantsCost SavingsFemaleHeparinHumansMaleMiddle AgedPlatelet Factor 4Professional RoleQuality ImprovementRisk ManagementUnited StatesAntibodiesAnticoagulantsHeparinPlatelet Factor 44T scoreAnticoagulationAnticoagulation stewardshipClinical decision support

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.